8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 13, 2026·SEC
Material company update
May 13, 2026·SEC
Anteris Technologies Global Corp.(AVR)Earnings, Financials & Key Ratios
AVR•NASDAQ
$9.69
Price updated Jun 27, 2026
AboutAnteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.Show more
- Revenue$2M-29.2%
- EBITDA-$92M-20.0%
- Net Income-$94M-23.4%
- EPS (Diluted)-4.00-6.1%
- Gross Margin-16.57%-135.4%
- EBITDA Margin-4821.38%-69.5%
- Operating Margin-4908.21%-69.3%
- Net Margin-4921.28%-74.4%
- ROE-301.6%-61.3%
AVR Price & Volume
Anteris Technologies Global Corp. (AVR) stock price & volume — 10-year historical chart
Loading chart...
Clinical Pivot Drives Severe Operational Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNegative: The company's persistent operating losses
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent capital dilution risk
"Anteris Technologies is currently undergoing a high-risk strategic transition toward the uncommercialized DurAVR system, resulting in significant operational losses and a reliance on external financing. While the company maintains a substantial cash position of $283.2M as of 2026Q1, the lack of stable revenue generation and persistent negative margins suggest that long-term viability remains contingent on successful regulatory milestones. Investors should monitor the company's ability to manage its $17.5M quarterly R&D expenditure against its accumulated deficit of $393.6M."
Verdict Logic
which exceeded $20M in 2026Q1, combined with a lack of commercialized revenue, present a high risk of further dilutive equity financing for shareholders.
AVR Growth Metrics
Anteris Technologies Global Corp. (AVR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-18.92%
3 Years-15.77%
TTM-25.74%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-16.5%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-38.89%
Return on Capital
10 Years-276.14%
5 Years-259.88%
3 Years-259.99%
Last Year-285.55%
AVR Recent Earnings
Anteris Technologies Global Corp. (AVR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 0/6 qtrs (0%)●Beat Revenue 2/6 qtrs (40%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.28-3.4%
$0.27
Rev
$494,000-35.6%
$766,667
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.75-49.0%
$0.50
Rev
$303,000+51.5%
$200,000
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.62-10.7%
$0.56
Rev
$429,000+39.5%
$307,500
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.58-16.0%
$0.50
Rev
$618,000-49.7%
$1M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.28vs $0.27-3.4% | $494,000vs $766,667-35.6% |
| Q1 2026 | Feb 26, 2026 | $0.75vs $0.50-49.0% | $303,000vs $200,000+51.5% |
| Q4 2025 | Nov 12, 2025 | $0.62vs $0.56-10.7% | $429,000vs $307,500+39.5% |
| Q3 2025 | Aug 11, 2025 | $0.58vs $0.50-16.0% | $618,000vs $1M-49.7% |
Based on last 6 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Anteris Technologies Global Corp. (AVR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $9.69 | $356.48M | -2.42 | -29.23% | -4921.28% | -301.6% | — | |
| $15.43 | $1.76B | -12.65 | 8.28% | -25.66% | -50.82% | — | |
| $4.46 | $289.33M | -4.80 | 1.59% | -29.44% | -69.5% | — | |
| $30.18 | $1.53B | -125.75 | 14.88% | -0.83% | -0.95% | — | |
| $90.78 | $52.27B | 49.61 | 11.55% | 17.34% | 10.54% | — | |
| $0.42 | $58.92M | 14.00 | 14.21% | 1.5% | 3.68% | — |
Compare AVR vs Peers
Anteris Technologies Global Corp. (AVR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AVR SEC Filings & Documents
Anteris Technologies Global Corp. (AVR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when AVR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AVR Frequently Asked Questions
Anteris Technologies Global Corp. (AVR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Anteris Technologies Global Corp.'s revenue?
Anteris Technologies Global Corp. (AVR) reported $1.9M in revenue for fiscal year 2025. This represents a 66% decrease from $5.5M in 2020.
How fast is Anteris Technologies Global Corp. growing?
Anteris Technologies Global Corp. (AVR) saw revenue decline by 29.2% over the past year.
Is AVR profitable?
Anteris Technologies Global Corp. (AVR) reported a net loss of $95.3M for fiscal year 2025.
Dividend & Returns
What is AVR's return on equity?
Anteris Technologies Global Corp. (AVR) has a return on equity (ROE) of -301.6%. Negative ROE indicates the company is unprofitable.
What is Anteris Technologies Global Corp.'s free cash flow?
Anteris Technologies Global Corp. (AVR) had negative free cash flow of $86.7M in fiscal year 2025, likely due to heavy capital investments.